Innovation Pharmaceuticals Inc (IPIX)

[SitTight]

New in vitro test against Chikungunya Virus show Brilacidin's potential one more time.

Study title: "New highly selective antivirals for Chikungunya Virus identified from the screening of a drug-like compound library"

https://www.biorxiv.org/content/10.1101/2024.05.17.594707v1?ct=
PDF download at https://www.biorxiv.org/content/10.1101/2024.05.17.594707v1.full.pdf

Four molecules were identified as potential drug candidates against CHIKV: MMV1634402 (Brilacidin) and MMV102270 (Diphyllin), which were previously shown to present broad-spectrum antiviral activities, in addition to MMV1578574 (Eravacycline), and the antifungal MMV689401 (Fluopicolide), for which their antiviral potential is uncovered here.

Conclusions:
Overall, our screening approach allowed identifying additional active hits against CHIKV within the PRB. Our results add new evidence on the broad-spectrum antiviral activities of some molecules that may interfere with viral entry and uncoating such as Brilacidin and Diphyllin, incorporates a new potential target for the antiviral action of a molecule with a possible anti cysteine-protease activity (Eravacycline) and introduce new perspectives on the potential use of Fluopicolide as an antiviral agent.

The study also thanks DNDI (Drugs for Neglected Diseases initiative) for its contribution. DNDI vows to invest over 600 mio Euro in the next years for its goal to deliver 15-18 new treatments for neglected diseases such as this!
https://dndi.org/about/strategy/

Would somebody please wake up Leo?